MEDIFA
MEDIFA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €3.39M and a net result of €887k. Equity is growing by ~26% per year across the filed fiscal years. Its solvency ranks better than 62% of 5424 sector peers (fiscal year 2025). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €3.39M |
| Net result | €887k |
| Better than sector | 62% |
| Active | 4 yrs |
Strong profile, led by profitability.
Computed on 4 of 5 axes. Not measured: health. An unmeasured axis is not a zero: no data was read for it.
This is a financial institution (bank, insurer or financial holding). Our bankruptcy model is trained on ordinary trading and manufacturing companies; a bank balance sheet falls outside that scope. We therefore show no bankruptcy probability rather than a misleading figure.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 64.7% | 51.8% | |
| Net result | €887k | €53k | |
| Equity | €3.39M | €622k | |
| Gross operating margin | €665k | €87k | |
| Total assets | €5.24M | €1.54M |
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Deposit | abbreviated schema | abbreviated schema | abbreviated schema |
| Revenue | n/a | n/a | n/a |
| EBITDA | n/a | n/a | n/a |
| Net profit | €887k | €786k | €11k |
| Cash flow | n/a | n/a | n/a |
| Staff costs | - | - | - |
| Income taxes | €190k | €177k | €5k |
| Dividends | - | - | - |
| Total assets | €5.24M | €4.71M | €4.20M |
| Equity | €3.39M | €2.67M | €2.00M |
| Debt | €1.85M | €2.05M | €2.20M |
| of which ≤ 1y | €894k | €724k | €508k |
| of which > 1y | €952k | €1.32M | €1.69M |
| Working capital | n/a | n/a | n/a |
| Employees (FTE) | - | - | - |
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Current ratio | n/a | n/a | n/a |
| Quick ratio | n/a | n/a | n/a |
| Working capital ratio | n/a | n/a | n/a |
| Solvency | 64.7% | 56.6% | 47.7% |
| Debt / equity | n/a | n/a | n/a |
| Long-term debt ratio | n/a | n/a | n/a |
| Interest coverage | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a |
| ROA | 16.9% | 16.7% | 0.3% |
| ROE | 26.2% | 29.5% | 0.6% |
| EBITDA margin | n/a | n/a | n/a |
| Days sales outstanding | n/a | n/a | n/a |
| Days payable outstanding | n/a | n/a | n/a |
| Inventory turnover | n/a | n/a | n/a |
| Days inventory (DSI) | n/a | n/a | n/a |
Full annual accounts (24 line items)
| Line item | Code | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Balance sheet, Assets | ||||
| TOTAL ASSETS | 20/58 | €5.24M | €4.71M | €4.20M |
| Fixed assets | 21/28 | €4.10M | €4.09M | €4.09M |
| Tangible fixed assets | 22/27 | €3k | - | - |
| Financial fixed assets | 28 | €4.09M | €4.09M | €4.09M |
| Current assets | 29/58 | €1.14M | €618k | €109k |
| Amounts receivable within one year | 40/41 | €1.10M | €587k | €98k |
| Cash & bank | 54/58 | €37k | €31k | €10k |
| Balance sheet, Equity & liabilities | ||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €5.24M | €4.71M | €4.20M |
| Equity | 10/15 | €3.39M | €2.67M | €2.00M |
| Contributions / capital | 10/11 | €1.99M | €1.99M | €1.99M |
| Reserves | 13 | €1.40M | €673k | €11k |
| Accumulated profits (losses) | 14 | €0 | €0 | - |
| Amounts payable | 17/49 | €1.85M | €2.05M | €2.20M |
| Amounts payable after one year | 17 | €952k | €1.32M | €1.69M |
| Amounts payable within one year | 42/48 | €894k | €724k | €508k |
| Trade debts payable within one year | 44 | €252k | €42k | €38k |
| Income statement | ||||
| Gross operating margin | 9900 | €665k | €621k | €102k |
| Operating result | 9901 | €663k | €621k | €101k |
| Financial income | 75 | €458k | €394k | - |
| Financial charges | 65 | €44k | €51k | €84k |
| Result before taxes | 9903 | €1.08M | €963k | €17k |
| Income taxes | 67/77 | €190k | €177k | €5k |
| Net result for the period | 9904 | €887k | €786k | €11k |
| Result to be appropriated | 9905 | €887k | €786k | €11k |
| NACE primary | Activities of holding companies(64210) |
| Legal form | Private limited company(610) |
| Incorporation | 28-04-2022 |
| Status | Active |
| Postal code | 9000 |
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44806F0425/00M003 | Flanders | 919 m² | 1 · 222 m² | 14.7 m · 5 fl. |
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
27-10-2022 Capital increase of €1,993,251.25 to €1,993,251.25
- €0 → €1.993.251,25
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 1993251.25,
"delta_eur": 1993251.25,
"before_eur": 0.0,
"subscribers": [
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "BOURAKADI, Farah",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": 19933,
"contribution_amount_eur": null
}
],
"_arith_derived": "before",
"share_emission": {
"agio_eur": null,
"share_form": "unknown",
"share_class": null,
"n_new_shares": 19933,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "inschrijvingsrechten_uitgifte",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Jeroen Uytterhaegen",
"firm_city": null,
"firm_name": null,
"office_city": "Wetteren",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2022-10-27",
"filing_date": "2022-10-25",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2022-10-12",
"unanimous": true,
"under_authorized_capital": true,
"underlying_resolution_date": null
},
"bedrijfsrevisor": {
"waived": false,
"firm_kbo": "0462.836.191",
"firm_name": "VANDERDONCKT - ROOBROUCK - CHRISTIAENS CVBA Bedrijfsrevisoren",
"ibr_number": null,
"mission_type": "apport_nature",
"individual_name": "Bart ROOBROUCK"
},
"subject_company": {
"kbo": "0785.526.685",
"name_full": "MEDIFA",
"legal_form": "Besloten Vennootschap",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "org",
"org_kbo": "0462.836.191",
"org_name": "VANDERDONCKT - ROOBROUCK - CHRISTIAENS CVBA Bedrijfsrevisoren",
"person_name": null,
"org_rep_person_name": "Bart ROOBROUCK",
"person_role_at_subject": null
},
"co_filed_documents": [
"uitgifte akte",
"bijzonder verslag van het bestuursorgaan",
"verslag van de bedrijfsrevisor"
],
"shareholders_after": [
{
"kbo": null,
"pct": null,
"kind": "person",
"name": "BOURAKADI, Farah",
"role": "aandeelhouder",
"n_shares": 19933,
"share_class": null
}
],
"share_classes_after": []
}| Legal nameNL | MEDIFA |